Breaking stock news, scored.

Breaking, market-moving stock news with AI analysis, updated every minute. Ticker-linked, relevance-scored, ready for your agent.

Score

Kospi opens lower ahead of earnings reports, Fed decision

The Kospi index opened lower on Monday, down 0.92%, as investors await earnings reports from SK hynix and Samsung Electronics, and the U.S. Federal Reserve's decision. The index lost 2.08% last week due to foreign selling and semiconductor volatility. Oil prices slightly declined from a six-month high.

AstraZeneca Readies New Portfolio of Targeted Cancer Therapies

AstraZeneca presented positive late-stage trial data for its first fully owned antibody-drug conjugate (ADC), sone-ve, showing a 42% reduction in death risk for advanced gastric cancer patients. The company plans to file for regulatory approval, aiming to strengthen its position in the fast-growing oncology market. AstraZeneca estimates peak revenue of $3B-$5B for sone-ve and over $5B for its broader ADC portfolio.

Solana stablecoin holders hit 14M as SOL falls 13%

Solana's stablecoin holders grew from 4M to 14M in October 2024, with total supply exceeding $15B. However, SOL's price fell 13% in 30 days, and DEX volume dropped 9%. Stablecoin flows remain mixed, with netflows near neutral. DeFi TVL is $5.77B, and daily fees are around $477k. Investors await increased activity to support SOL's price recovery.

$HCMHighAI 8/10

A two-drug lung cancer treatment extended median survival by 4.9 months

HUTCHMED and AstraZeneca announced positive Phase III trial results for ORPATHYS® (savolitinib) plus TAGRISSO® (osimertinib) in EGFR-mutated NSCLC with MET overexpression. The combo extended median overall survival by 4.9 months and reduced disease progression risk. Results were presented at ESMO and published in NEJM. NDAs have been submitted in the US, with submissions in Europe and Japan planned. ORPATHYS® is jointly developed by both companies and commercialized by AstraZeneca.

$005930.KSLow

"Perfect for wearing during workouts"…Samsung Unveils Clip-Style Wireless Earbuds, 'Galaxy Buds On'

Samsung Electronics launched the 'Galaxy Buds On,' clip-style wireless earbuds priced at 299,000 won, available from the 27th. Features include a comfortable fit, rich sound, and clear call quality. Purchases come with discounts on accessories. The product is compatible with 'Galaxy Buds4 series' accessories and offers hands-free functions when connected to Galaxy AI devices.